JW (CAYMAN) THERAPEUTICS CO. LTD Funds and ETFs JW (Cayman) Therapeutics Co. Ltd
Equities
2126
KYG5210T1040
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.83 HKD | +0.55% |
|
+4.57% | -19.03% |
| Mar. 20 | JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023 | MT |
| Mar. 20 | JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
ETFs positioned on JW (Cayman) Therapeutics Co. Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.70% | 4 M€ | -27.92% |
JW Cayman Therapeutics Co Ltd is a China-based company mainly engaged in the clinical and pre-clinical stage cell therapy. The Company is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The Company mainly conducts its businesses in the China market.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.683
CNY
Average target price
2.508
CNY
Spread / Average Target
+48.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.03% | 93.83M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.46% | 22.18B | |
| -16.67% | 21.2B | |
| -8.58% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- 2126 Stock
- Funds and ETFs JW (Cayman) Therapeutics Co. Ltd
